Evidence map›Paper›PMID 32865808›Full record

ArticleTherapeutic innovation & regulatory science2020

Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

Thomas Severin, Solange Corriol-Rohou, Christina Bucci-Rechtweg, Kristina An Haack, Sabine Fuerst-Recktenwald, Pirkko Lepola, Ensio Norjavaara, Martine Dehlinger-Kremer, EFGCP Children’s Medicines Working Party, Sebastian Haertter and 2 more

Abstract readPublished Erratum
In one paragraph

Article in Therapeutic innovation & regulatory science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Thomas SeverinGlobal Drug Development, Novartis Pharma AG, Novartis Campus, 4002, Basel, Switzerland. thomas.severin@novartis.com.
Solange Corriol-RohouGlobal Regulatory Excellence, AstraZeneca, Paris, France.
Christina Bucci-RechtwegGlobal Health Policy, Regulatory Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Kristina An HaackR&D/Clinical Development Rare Diseases, Sanofi/Genzyme, Chilly-Mazarin, France.
Sabine Fuerst-RecktenwaldProduct Development Neurology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Pirkko LepolaDepartment of Children and Adolescents, Helsinki University Hospital, Helsinki, Finland.
Ensio NorjavaaraGlobal Medicines Development, AstraZeneca, Mölndal, Sweden.
Martine Dehlinger-KremerPediatric Development, Synteract, & EUCROF, Munich, Germany.
EFGCP Children’s Medicines Working Party
Sebastian HaertterTranslational Medicine & Clinical Pharmacology, Boehringer-Ingelheim, Ingelheim, Germany.
S Y Amy CheungCertara, Princeton, NJ, USA.
IQ Pediatric Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement, written by Thomas Severin et al. was originally published electronically on the publisher's internet portal on February 6, 2020 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on April 22, 2020 to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Identifiers

PMID32865808
PMCPMC7645507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.